Eli Lilly reports promising data for alopecia and eczema drugs, eyes label expansion

Core Insights - Eli Lilly announced safety and efficacy results from two late-stage studies for its approved drugs targeting alopecia and eczema [1] Group 1 - The studies are focused on evaluating the performance of existing medications in treating alopecia and eczema [1]